SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology. 1994;44: S4S5.
  • 2
    American Psychiatric Association. Work Group on DSM-IV-PC, American Academy of Family Physicians. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Primary Care Version, 1st ed. Washington, DC: American Psychiatric Association; 1995.
  • 3
    Feldman MD. Munchausen by Internet: detecting factitious illness and crisis on the Internet. South Med J. 2000;93: 669672.
  • 4
    Adler A. Understanding Human Nature. New York: Greenberg; 1927.
  • 5
    Selye H. The Stress of Life. Rev. ed. New York: McGraw-Hill; 1978.
  • 6
    Cannon WB. The Wisdom of the Body. New York: W. W. Norton & Company; 1939:xviii, 19–333.
  • 7
    Bernard C. An Introduction to the Study of Experimental Medicine. Mineola, NY: Dover Publications; 1927.
  • 8
    Pavlov IP. Experimental Psychology, and Other Essays. New York: Philosophical Library; 1957.
  • 9
    Alexander F, Benedek T. Psychosomatic Medicine, Its Principles and Applications, 1st ed. New York: Norton; 1950.
  • 10
    Wolff HG. Headache and Other Head Pain, 2nd ed. New York: Oxford University Press; 1963.
  • 11
    Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psych Res. 1991;37: 1123.
  • 12
    Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is the association specific to migraine? Neurology. 2000;54: 308313.
  • 13
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psych. 1994;51: 819.
  • 14
    Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151: 979986.
  • 15
    Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277: 333340.
  • 16
    Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. J Clin Psych. 1993;54: 419424.
  • 17
    Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psych. 1993;54: 405418.
  • 18
    Agency for Health Care Policy and Research. Depression in Primary Care. Vol. 2. Treatment of Major Depression. Rockville, MD: AHCPR; 1993.
  • 19
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6: 278296.
  • 20
    Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12: 6370.
  • 21
    Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7: 151169.
  • 22
    Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272: 17491756.
  • 23
    Greene RL. MMPI-2: An Interpretive Mannual, 2nd ed. Needham Heights, MA: Allyn & Bacon; 1999.
  • 24
    Krishnan K. Depression as a contributing factor to cardiovascular disease [abstract]. Am Heart J. 2000;140: 7076.
  • 25
    Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55: 629635.
  • 26
    Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry. 1994;55(suppl):3444.
  • 27
    Marcus DA. Serotonin and its role in headache pathogenesis and treatment. Clin J Pain. 1993;9: 159167.
  • 28
    Goadsby PJ. The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci. 1999;26(suppl 3):S20S26.
  • 29
    Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol. 2000;15: 171181.
  • 30
    Peroutka SJ. Dopamine and migraine. Neurology. 1997;49: 650656.
  • 31
    Barbanti P, Fabbrini G, Ricci A, et al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia. 2000;20: 1519.
  • 32
    Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics. 2000;3: 3540.
  • 33
    Seligman MEP. Helplessness: On Depression, Development and Death. San Francisco: W. H. Freeman and Company; 1975.
  • 34
    Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55: 754762.
  • 35
    Advisory Committee of the Primary Care Network. Patient-centered strategies for effective management of migraine. Springfield, MO: PCN; 2000. http://www.primarycarenet.org/pcs
  • 36
    Coyne JC, Pepper CM, Flynn H. Significance of prior episodes of depression in two patient populations. J Consult Clin Psychol. 1999;67: 7681.
  • 37
    Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 1998;7: 443449.
  • 38
    Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000;45: 476481.
  • 39
    Pinsker W. Potentially safe and effective new treatment for migraine? Headache. 1993;33: 163.
  • 40
    Kaniecki RG. Nefazodone in the prophylaxis of migraine: a prospective open label trial [poster 42]. Presented at the 40th Annual Scientific Meeting The American Association for the Study of Headache, San Francisco, Calif., June 26-28, 1998.
  • 41
    Davidoff RA. Migraine: Manifestation, Pathogenesis, and Management. Philadelphia, PA: F. A. Davis; 1995.
  • 42
    Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache. 2000;40: 572580.
  • 43
    Slaby AE, Tancredi LR. Micropharmacology: treating disturbances of mood, thought, and behavior as specific neurotransmitter dysregulations rather than as clinical syndromes. Prim Psych. 2001;8: 2832.
  • 44
    Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry. 1994;151: 413420.
  • 45
    Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psych. 1989;46: 984992.
  • 46
    Johnson MR, Lydiard RB, Ballenger JC. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995;49: 328344.
  • 47
    Saper J, Sheftell F. Headache in the abuse-prone individual. In: OlesenJ, Tfelt-HansenP, WelchKMA, eds. The Headaches, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000: 953958.
  • 48
    Martin NJ, Holroyd KA, Penzien DB. The headache-specific locus of control scale: adaptation to recurrent headaches. Headache. 1990;30: 729374.
  • 49
    French DJ, Holroyd KA, Pinell C, Malinoski PT, O'Donnell F, Hill KR. Perceived self-efficacy and headache-related disability. Headache. 2000;40: 647656.